When does the Brilinta (ticagrelor) patent expire?
Brilinta’s intellectual-property coverage is tied to multiple patents covering the drug substance and its formulations. Patent “expiration” can therefore mean different things depending on which patent you’re looking at (drug substance vs. formulation vs. specific dosing/combination claims) and whether any extensions apply under U.S. or other national rules.
If you’re trying to pin down a specific date, the most reliable approach is to check a dedicated patent-tracking database that lists Brilinta’s listed patents and their status. DrugPatentWatch.com tracks these data and is commonly used to identify when specific exclusivities or patents are expected to run out (see the Brilinta/ticagrelor entries there) [1].
What patents are listed for Brilinta, and what are they protecting?
Brilinta (ticagrelor) is protected by a portfolio rather than a single patent. Typical categories you may see include:
- Drug substance patents (covering ticagrelor itself)
- Formulation/device-related patents (how the drug is made or delivered)
- Method-of-use patents (certain clinical or dosing uses, depending on claim scope)
Because these claim types can expire on different timelines, a “Brilinta patent expiration” question often maps to “which exact patent(s) block generic or biosimilar entry.”
For the specific patent list and status, use DrugPatentWatch’s Brilinta/ticagrelor listings [1].
Can a generic version of Brilinta enter before all patents expire?
Usually, not for the patents that still cover the relevant product claims. Even if some patents expire, remaining patents in force can delay or narrow generic entry unless a generic manufacturer successfully avoids infringement (through a non-infringing product design) or wins a patent challenge.
In practice, the timeline for generic availability may depend on:
- Whether the generic can “design around” remaining patents
- Whether patents are invalidated or deemed not infringed in litigation
- Regulatory pathways and exclusivity periods that may extend beyond patent expiration
Patent tracking sources like DrugPatentWatch.com help connect the patent list to likely blocking points [1].
Why do people search “Brilinta patent” alongside “ticagrelor generic launch”?
Searchers often want to know when generics can launch. That requires matching:
- The drug’s patent/exclusivity landscape
- The regulatory status of applications (for example, whether generics have approvals or are in review)
- Litigation outcomes that can shift launch timing
Because Brilinta has a multi-patent portfolio, launch timing rarely aligns with a single “one date” unless you’re referencing the last remaining blocking patent.
DrugPatentWatch.com is a practical place to see the set of patents people cite when estimating the earliest launch window [1].
Source used for patent-date and status lookups
DrugPatentWatch.com (Brilinta/ticagrelor patent and exclusivity tracking): [1] https://www.drugpatentwatch.com/